Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma

doi:10.3748/wjg.v20.i35.12581

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 35

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4830)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-4) series.

Item

Count

PDF

424

WORD

239

HTML

3066

Figures (1-4)

111

Tables (1-4)

108

Sum=3948

Sep 21, 2014 (publication date) through Apr 25, 2024

Times Cited of This Article

Times Cited (28)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. Sep 21, 2014; 20(35): 12581-12587
Published online Sep 21, 2014. doi: 10.3748/wjg.v20.i35.12581

Open in New Tab Full Size Figure Download Figure

Figure 1 Overall survival and time to progression. A: Overall survival; B: Time to progression of all patients enrolled in this study was estimated using Kaplan-Meier analysis.

Open in New Tab Full Size Figure Download Figure

Figure 2 Hepatocellular carcinoma etiology in relation to overall survival and time to progression. A: Overall survival (OS); B: Time to progression (TTP) were analyzed according to the etiology of hepatocellular carcinoma (HCC). HBV: Hepatitis B virus; HCV: Hepatitis C virus.

Open in New Tab Full Size Figure Download Figure

Figure 3 Relationship of clinical factors with time to progression. Time to progression (TTP) was analyzed according to A: Child-Pugh grade; B: Location of largest hepatocellular carcinoma; C: Size of the largest tumor, and the occurrence of D: Hand-foot syndrome; E: Hypertension; F: Diarrhea; G: Alopecia.

Open in New Tab Full Size Figure Download Figure

Figure 4 Relationship of starting sorafenib dose with time to progression. Time to progression (TTP) was analyzed according to sorafenib dose at the beginning of the treatment.

Citation: Yada M, Masumoto A, Motomura K, Tajiri H, Morita Y, Suzuki H, Senju T, Koyanagi T. Indicators of sorafenib efficacy in patients with advanced hepatocellular carcinoma. World J Gastroenterol 2014; 20(35): 12581-12587
URL: https://www.wjgnet.com/1007-9327/full/v20/i35/12581.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i35.12581